Sernova Biotherapeutics Advances Toward Diabetes Solutions with FDA Orphan Drug Designation and Strengthened Capital Base
Source: Streetwise Reports  (6/19/26)
Sernova Biotherapeutics leverages its Cell Pouch technology and recent FDA orphan drug designation to address type 1 and type 3c diabetes amid a growing global market, supported by improved financial stability for retail investors. More >

Biopharma Co. Hits Regulatory Hurdle in High-Priority Bird Flu Program
Source: Streetwise Reports  (6/19/26)
Traws Pharma, Inc.'s (TRAW:NASDAQ) bird flu antiviral hits a U.K. regulatory hurdle, delaying its Phase 2a study and prompting an analyst downgrade from Buy to Neutral. More >

Biopharma Developer Unveils Breakthrough Hypoglycemia Treatment Data
Source: Streetwise Reports  (6/19/26)
Rezolute Inc. (RZLT:NASDAQ) presented promising data at ENDO 2026, with analysts eyeing big gains and a "Buy" rating as Phase 3 study results loom in the second half of 2026. More >

Biotech Secures Major FDA Orphan Drug Designation for Diabetes Treatment
Source: Streetwise Reports  (6/18/26)
Sernova Biotherapeutics Inc. (SVA:TSX.V; SEOVF:OTC; PSH:XETRA) announces it has been granted orphan drug designation for autologous islet transplantation (AIT) for preventing diabetes following a total pancreatectomy. More >

enGene Therapeutics Positions Detalimogene for NMIBC Opportunity Amid Expanding Oncology Landscape
Source: Streetwise Reports  (6/18/26)
Explore how enGene Therapeutics is advancing its novel gene therapy, Detalimogene, for bladder cancer within a growing oncology market, including clinical progress, financial strength, and upcoming catalysts for investors. More >

Teva Pharmaceutical Advances Neuroscience Pipeline With Strong AUSTEDO Growth and New Acquisition
Source: Streetwise Reports  (6/17/26)
Teva Pharmaceutical Industries reports robust first-quarter revenue growth from AUSTEDO and specialty products while closing the Emalex acquisition and advancing multiple late-stage programs in neuroscience, immunology, and respiratory diseases for retail investors. More >

Oncology BioPharma Co. Reports Mixed Trial Data, Plots Path to FDA
Source: Streetwise Reports  (6/17/26)
enGene Therapeutics Inc. (ENGN:NASDAQ) shared Q2 results and LEGEND trial updates for detalimogene, its non-muscle invasive bladder cancer therapy, as analysts waver on stock. More >

A New Pharma Giant Goes Public as a Sector Leader Makes Moves in Neuroscience
Source: Streetwise Reports  (6/16/26)
Apotex Health Corp. (APTX:TSX) raised approximately CA$1.3 billion in its IPO while Teva Pharmaceutical Industries Ltd. (TEVA:NYSE) reported new AUSTEDO data and added a late-stage Tourette syndrome asset. More >

Nuvalent Acquisition by GSK Highlights Growing Opportunities in Targeted Oncology Therapies
Source: Streetwise Reports  (6/16/26)
Explore how the pending GSK acquisition of Nuvalent at a premium underscores sector momentum in precision oncology, with key pipeline catalysts and market trends for retail investors to consider. More >

Analysts Cut Biopharma Co. to Neutral After Pending US$10.6B Deal
Source: Streetwise Reports  (6/15/26)
Analysts downgrade Nuvalent Inc (NUVL:NASDAQ) to "Neutral" after GSK's US$10.6B all-cash buyout offer at US$124/share, calling the deal favorable but a competing bid unlikely. More >

Oculis Holding AG Pioneers Genotype-Based Precision Approach to Dry Eye Disease Treatment
Source: Streetwise Reports  (6/13/26)
Oculis Holding AG launches the PREDICT-1 trial for licaminlimab, targeting patients with a specific TNFR1 genotype to address unmet needs in the large dry eye disease market. More >

MindBio Therapeutics Positions Voice AI Technology for Growth in Safety-Critical Sectors
Source: Streetwise Reports  (6/12/26)
Explore how MindBio Therapeutics is advancing voice-based AI detection for intoxication across mining, aviation, and other industries, backed by strong market trends and analyst targets. More >

Biopharma Co. Trials Precision Medicine Breakthrough for Dry Eye Disease. Gets Positive Results
Source: Streetwise Reports  (6/12/26)
Oculis Holding AG (OCS:NASDAQ; OCS:XICE) launches PREDICT-1, a genotype-based trial for licaminlimab, targeting 10M moderate-to-severe dry eye patients. More >

Biotech Firm Deploys Revolutionary Intox AI, Unlocking Billion-Dollar Industrial Safety Opportunity
Source: Streetwise Reports  (6/10/26)
MindBio Therapeutics Corp. (MBIO:CSE; MBQIF:OTCQB; WF6:Frankfurt) launches Intox AI, detecting intoxication via voice, targeting mining and aviation in a US$2.06B market. More >

ORIC Pharmaceuticals Positions for Growth in Expanding Oncology Market
Source: Streetwise Reports  (6/10/26)
Explore how ORIC Pharmaceuticals is advancing its oncology pipeline with key catalysts ahead, amid rising global demand for innovative cancer treatments and strong analyst support. More >

Clinical-Stage Biopharma Co. Issues New Inducement Stock Options for Growth
Source: Streetwise Reports  (6/8/26)
ORIC Pharmaceuticals Inc. (ORIC:NASDAQ) granted 34,800 stock options and 5,900 restricted stock units to new employees as analysts issue "Buy" ratings for the year ahead. More >

Cancer Drug Developer Shifts 70% of Spending to Research as AI Pipeline Progresses
Source: Streetwise Reports  (6/5/26)
Rakovina Therapeutics (TSX.V: RKV) reported lower net losses, reduced administrative spending, debt restructuring, financing activity, and progress across its AI-driven oncology pipeline in Q1 2026. More >

California Pharma Co. Tests Breakthrough Cancer Drug, Cuts Death Risk 60%
Source: Streetwise Reports  (6/4/26)
Revolution Medicines Inc.'s (RVMD:NASDAQ) daraxonrasib treats pancreatic cancer patients, doubling median survival. Analysts rate it a "Buy" with targets up to US$263. More >

US Biotech Co. Targets Muscular Dystrophy with First-In-Class Drug
Source: Streetwise Reports  (6/1/26)
Capricor Therapeutics Inc.'s (CAPR:NASDAQ) Deramiocel targets FDA approval by August 2026, with analysts issuing Buy ratings and price targets as high as US$60. More >

Biopharma Company Reveals High-Impact SCI Recovery Gains
Source: Streetwise Reports  (5/28/26)
NervGen Pharma Corp. (NGEN:TSX.V; NGENF:OTCQX) reports 100% responder rates for NVG-291 in spinal cord injury trials, strengthening hopes for major recovery breakthroughs. More >

Cleantech Co. Wins PFAS Deal, Engineering Pact, Ships Clyra
Source: Richard Ryan  (5/21/26)
BioLargo (BLGO:OTCQX) shipped Clyra's first stocking order, signed Aquatech PFAS MOU, and won a US$1.2M engineering contract for a minerals processing facility, according to an Oak Ridge Financial research note More >

Lexington, MA Biotech Pushes DMD Phase 2 Start to 3Q26 on Regulatory Hurdles
Source: Dr. Yun Zhong  (5/20/26)
Keros Therapeutics (KROS:NASDAQ) disclosed that initiation of its Phase 2 rinvatercept study in Duchenne muscular dystrophy will slip from 2Q26 to 3Q26 due to procedural regulatory delays, according to a Wedbush research note. More >

Lexington, MA Biopharma Co. Reports Q1 2026 Financials, Makes R&D Plans
Source: Streetwise Reports  (5/20/26)
Keros Therapeutics Inc. (KROS:NASDAQ) lowered research spending & reported funding through 2028 as analysts monitor upcoming trial catalysts for ALS & Muscular Dystrophy drugs. More >

FDA Fast Track Designation Boosts ALS Treatment Outlook; Analyst Sees More Than 250% Upside Potential
Source: Jason Kolbert  (5/12/26)
D. Boral Capital analyst Jason Kolbert reiterated his rating and price target on Coya Therapeutics Inc. (COYA:NASDAQ) following the company's receipt of FDA Fast Track Designation for COYA 302 in ALS. More >

California Biotech Co. Discovers VOXZOGO Breakthrough, Reports Strong Q1
Source: Streetwise Reports  (5/11/26)
BioMarin Pharmaceuticals Inc. (BMRN:NASDAQ) delivered positive long-term achondroplasia data alongside rising revenues, accelerating rare disease portfolio growth. More >